Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Zacks News
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 12.50% and 11.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endo (ENDP) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Health Care ETFs Outperforming XLV on YTD Basis
by Zacks Equity Research
Health care ETFs provide handsome returns year to date.
Is Nektar Therapeutics (NKTR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NKTR) Outperforming Other Medical Stocks This Year?
High Beta, Momentum ETFs & Stocks to Trade in a Market Rally
by Sweta Killa
While the rally seems to be broad-based, high beta and high momentum products are expected to lead the market.
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
by Zacks Equity Research
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Nektar Therapeutics (NKTR) Q2 Earnings Meet Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 0.00% and 4.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Nektar Therapeutics (NKTR) Might Surprise This Earnings Season
by Zacks Equity Research
Nektar Therapeutics (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?
by Zacks Equity Research
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales.
Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5%
by Zacks Equity Research
Nektar Therapeutics (NKTR) shares rose nearly 7% in the last trading session, amid huge volumes.
Company News For Jun 5, 2018
by Zacks Equity Research
Companies in the news are: GHDX,BAYN.DE, NKTR,DCPH
Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nektar (NKTR) stock based on the movements in the options market lately.
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.